Adage Capital Partners Gp, L.L.C. Inozyme Pharma, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 5,728,856 shares of INZY stock, worth $27.4 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
5,728,856
Previous 5,328,856
7.51%
Holding current value
$27.4 Million
Previous $40.8 Million
37.41%
% of portfolio
0.05%
Previous 0.08%
Shares
15 transactions
Others Institutions Holding INZY
# of Institutions
93Shares Held
52.4MCall Options Held
17.6KPut Options Held
2.7K-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA4.49MShares$21.5 Million18.06% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA4.28MShares$20.5 Million1.06% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.94MShares$18.8 Million0.31% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3.7MShares$17.7 Million0.51% of portfolio
-
Samlyn Capital, LLC New York, NY3.35MShares$16 Million0.27% of portfolio
About Inozyme Pharma, Inc.
- Ticker INZY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,145,700
- Market Cap $192M
- Description
- Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...